Story thread · 6 reports / 2 sources
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge
investing.com · 15d
First report: MacroGenics slips after early-stage trial data for lead asset — seekingalpha.com, 18d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.